Conference name
Exhibitors & Sponsors




Mogens Vyberg

EQA of lung carcinoma analyses

Handout (pdf 36 p)  Handout (pdf 9 p)


Over-all, 25%-50% of stains submitted to NordiQC are marked optimal and up to about 30% are insufficient. For optimal staining reactions, selection of well performing antibodies, correctly calibrated dilution, efficient HIER, and a sensitive visualization system are required. Diagnostic markers for the subclassification of lung carcinomas include: Thyroid transcription factor-1 (TTF-1), Napsin A, Cytokeratin (CK) high molecular weight (HMW), primarily type CK5, and p63 or p40. These have all been included in one or more NordiQC challenges, the results of which are detailed on (p40 to be published in July 2015). For TTF-1 clones SPT24 and SP141 gave the best results, while clone 8G7G3/1 gave a pass rate of only 13%. For Napsin A clone IP64 was the most robust, For CK-HMW clone 34BE12 gave an insufficient, most often false positive staining, and for p63 clones DAK-p63 and 4A4 both provided a high pass rate, especially as Ready-To-Use systems, while clone 7JUL showed poor performance.

EQA of malignant mesothelioma marker analyses

Diagnostic markers for identification of malignant mesothelioma include: Calretinin (CR), Podoplanin (PDP) and Wilms' tumour-1 (WT-1). These have all been included in one or more NordiQC challenges, the results of which are detailed on For all tests, major reasons for insufficient stains were too low concentration of the primary antibody and use of low sensitive detection systems. Furthermore, less successful performance on the Ventana BenchMark platform  were seen with clone DAK-Calret 1 (for CR), clone D2-40 (for PDP) and clone 6F-H2 (for WT-1).


Dr. Mogens Vyberg graduated in 1973, completed residencies in Anatomic and Clinical Pathology at hospitals associated with University of Copenhagen, and was board-certified 1984. Since 1988 he has been senior consultant at the Institute of Pathology, Aalborg Hospital and was appointed as professor of clinical pathology at Aalborg University in 2012.
Dr. Vyberg’s main research fields and clinical expertise are immunohistochemistry and gastrointestinal, liver and brain pathology. He is author and co-author of more than 80 scientific papers and several book chapters in these fields as well as the text book Compendium of Applied Immunohistochemistry (Danish; English version scheduled for 2016). He is head of the Laboratory for immunohistochemistry/R&D, which carries out quality control and protocol optimization for the world’s leading diagnostics companies.
Dr. Vyberg is co-founder and scheme director of the international organization Nordic Immunohistochemical Quality Control (NordiQC), which was established in 2003 with Aalborg Hospital as its domicile and currently serves about 700 pathology laboratories from more than 40 countries.

Exhibitors & Sponsors